Physicians reveal their prescribing choices and the anticipated impact of new therapies in MS
- What are the trends in the number of patients presenting and diagnosis of MS and MS sub types?
- Which therapies are physicians currently using to treat MS?
- What drivers for change do physicians identify that could disrupt the MS market?
- Which product attributes most influence a physician’s choice of therapy?
- How do physicians view new therapies and which clinical trials are seen as being important?
A number of new therapies are poised to enter the Multiple Sclerosis (MS) market adding yet more options to the MS treatment portfolio. But what impact will new treatments such as EMD Serono’s Mavenclad and Novartis’ Mayzent have on established products such as Roche’s Ocrevus and Biogen’s Tysabri? What influences physicians’ prescribing choices and how can pharma react to drive greater use of their products?
The bar for success in MS is set high and establishing or defending a market position requires optimum clinical and patient benefits. With this comprehensive quantitative study Future Treatment Trends in Multiple Sclerosis (Physician Survey), you can understand, at the product level, the current prescribing practice and future intentions of 200 front-line neurologists in the US, Germany, France and the UK.
This cutting-edge survey report is rich in tables, charts and analysis and provides clear, actionable intelligence to inform pharma’s commercial and communications strategies.
200 experienced neurologists speak out on key issues:
- Why are some physicians more likely to treat patients transitioning to SPMS differently to established patients?
- Approval of new therapies? Better understanding of disease? Improved diagnostics? What are the key drivers that could change physician approaches to diagnosis and classification?
- Interferon? Copaxone? Tecfidera? Ocrevus? Tysabri? Which products do physicians employ for treating RRMS, SPMS and PPMS and what are the variations in practice between the US and EU3?
- Efficacy? Safety? Dosing? Cost? What are a product’s attributes that win physician support and what brands are favoured and why?
- How do physicians rate Mayzent, Mavenclad, Vumerity and ofatumumab?
- In RRMS, SPMS and PPMS which products stand to lose the most market share from early adoption of newer therapies and how big will the impact be?
- Among current users and non-users of Ocrevus, how relevant are the CONSONANCE and ORATORIO-HAND clinical trials?
MS sectors covered in this survey report
- Relapsing-Remitting MS (RRMS}
- Primary-Progressive MS (PPMS)
- Secondary-Progressive MS (SPMS)
MS products covered in this survey report?
- Interferon [generic]
- Tecfidera (dimethyl fumarate) [Biogen]
- Copaxone (glatiramer acetate) [Teva Pharmaceuticals]
- Gilenya (fingolimod) [Novartis]
- Tysabri (natalizumab) [Biogen]
- Aubagio (teriflunomide) [Genzyme]
- Ocrevus (ocrelizumab) [Roche]
- Lemtrada (alemtuzumab) [Sanofi/Genzyme]
- rituximab [generic]
Recent and pipeline products
- Mavenclad (cladribine) [EMD Serono]
- Mayzent (siponimod) [Novartis]
- ofatumumab [Novartis]
- ozanimod [Celgene]
- Vumerity (diroximel fumarate) [Alkermes/Biogen]
About the expert neurologists who responded
100 US and 100 EU3 (UK, Germany and France) neurologists contributed to this survey. All the respondents…
- Are neurologists with 2-40 years in practice
- Spend at least half their time treating patients
- Have treated at least 10 adult MS patients in the past month
Why choose FirstViews Physician Survey Reports?
FirstView’s highly-valuable physician survey reports unlock critical physician insights and;
- Provide a unique physician perspective on key clinical and prescribing issues of importance to pharma
- Are based on quantitative primary research to reliably reveal the widest range of opinion
- Reflect only the views of screened physicians who are fully qualified to meaningfully contribute to the survey subject